First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

Julie A. Kelly, Noreen T. Boyle, Natalie Cole, Gillian R. Slator, M. Alessandra Colivicchi, Chiara Stefanini, Oliviero L. Gobbo, Gaia A. Scalabrino, Sinead M. Ryan, Marwa Elamin, Cathal Walsh, Alice Vajda, Margaret M. Goggin, Matthew Campbell, Deborah C. Mash, Shane M. O'Mara, David J. Brayden, John J. Callanan, Keith F. Tipton, Laura Della Corte, Jackie Hunter, Kathy M. O'Boyle, Carvell H. Williams, Orla Hardiman
  • Neuropharmacology, February 2015, Elsevier
  • DOI: 10.1016/j.neuropharm.2014.09.024

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Professor Shane M O'Mara